252 related articles for article (PubMed ID: 32064779)
21. Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.
Lee LY; Zhou J; Koszalka P; Frise R; Farrukee R; Baba K; Miah S; Shishido T; Galiano M; Hashimoto T; Omoto S; Uehara T; Mifsud EJ; Collinson N; Kuhlbusch K; Clinch B; Wildum S; Barclay WS; Hurt AC
PLoS Pathog; 2021 May; 17(5):e1009527. PubMed ID: 33956888
[TBL] [Abstract][Full Text] [Related]
22. Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season.
Ikematsu H; Kawai N; Tani N; Chong Y; Iwaki N; Bando T; Tanaka O; Matsuura S; Maeda T; Doniwa K
J Infect Chemother; 2020 Apr; 26(4):400-402. PubMed ID: 31870588
[TBL] [Abstract][Full Text] [Related]
23. Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility.
Hickerson BT; Petrovskaya SN; Dickensheets H; Donnelly RP; Ince WL; Ilyushina NA
J Virol; 2023 Jul; 97(7):e0015423. PubMed ID: 37404185
[TBL] [Abstract][Full Text] [Related]
24. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
[TBL] [Abstract][Full Text] [Related]
25. Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model.
Park JH; Kim B; Antigua KJC; Jeong JH; Kim CI; Choi WS; Oh S; Kim CH; Kim EG; Choi YK; Baek YH; Song MS
Antiviral Res; 2021 Sep; 193():105126. PubMed ID: 34217753
[TBL] [Abstract][Full Text] [Related]
26. Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods.
Patel MC; Mishin VP; De La Cruz JA; Chesnokov A; Nguyen HT; Wilson MM; Barnes J; Kondor RJG; Wentworth DE; Gubareva LV
Antiviral Res; 2020 Oct; 182():104906. PubMed ID: 32798601
[TBL] [Abstract][Full Text] [Related]
27. The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
Taniguchi K; Noshi T; Omoto S; Sato A; Shishido T; Matsuno K; Okamatsu M; Krauss S; Webby RJ; Sakoda Y; Kida H
Arch Virol; 2024 Jan; 169(2):29. PubMed ID: 38216710
[TBL] [Abstract][Full Text] [Related]
28. Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018-2019 Influenza Season.
Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Hashimoto K; Hosoya M
J Infect Dis; 2020 Jun; 222(1):121-125. PubMed ID: 32034420
[TBL] [Abstract][Full Text] [Related]
29. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019.
Takashita E; Ichikawa M; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Sugawara H; Sato A; Akimoto M; Mitamura K; Abe T; Yamazaki M; Watanabe S; Hasegawa H; Odagiri T
Emerg Infect Dis; 2019 Nov; 25(11):2108-2111. PubMed ID: 31436527
[TBL] [Abstract][Full Text] [Related]
30. Polymerase Acidic Subunit I38T Mutant Influenza A(H3N2) Virus Isolated from a Pediatric Patient without Prior Baloxavir Marboxil Treatment in Mie Prefecture (November 2018).
Yano T; Ochiai H; Akachi S; Matsumura Y
Jpn J Infect Dis; 2020 Sep; 73(5):383-385. PubMed ID: 32475868
[No Abstract] [Full Text] [Related]
31. Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.
Chesnokov A; Patel MC; Mishin VP; De La Cruz JA; Lollis L; Nguyen HT; Dugan V; Wentworth DE; Gubareva LV
J Infect Dis; 2020 Jan; 221(3):367-371. PubMed ID: 31541547
[TBL] [Abstract][Full Text] [Related]
32. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
Shirley M
Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915
[TBL] [Abstract][Full Text] [Related]
33. Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
Abed Y; Saim-Mamoun A; Boivin G
Rev Med Virol; 2021 May; 31(3):e2175. PubMed ID: 32975358
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil.
Hashimoto T; Baba K; Inoue K; Okane M; Hata S; Shishido T; Naito A; Wildum S; Omoto S
Influenza Other Respir Viruses; 2021 May; 15(3):389-395. PubMed ID: 33099886
[TBL] [Abstract][Full Text] [Related]
35. Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
Jones JC; Rovito SW; Penaflor MK; Webby RJ; Govorkova EA
Antiviral Res; 2022 Aug; 204():105369. PubMed ID: 35738347
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.
Takashita E; Morita H; Ogawa R; Nakamura K; Fujisaki S; Shirakura M; Kuwahara T; Kishida N; Watanabe S; Odagiri T
Front Microbiol; 2018; 9():3026. PubMed ID: 30574137
[TBL] [Abstract][Full Text] [Related]
37. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
Chong Y; Kawai N; Tani N; Bando T; Takasaki Y; Shindo S; Ikematsu H
Antiviral Res; 2021 Aug; 192():105092. PubMed ID: 34052230
[TBL] [Abstract][Full Text] [Related]
38. Mutated influenza A virus exhibiting reduced susceptibility to baloxavir marboxil from an experimentally infected horse.
Nemoto M; Tamura N; Bannai H; Tsujimura K; Kokado H; Ohta M; Yamanaka T
J Gen Virol; 2019 Nov; 100(11):1471-1477. PubMed ID: 31526451
[TBL] [Abstract][Full Text] [Related]
39. Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
Wagatsuma K; Saito R; Chon I; Phyu WW; Fujio K; Kawashima T; Sato I; Saito T; Minato M; Kodo N; Suzuki E; Ono Y; Masaki H; Shirahige Y; Kitano A; Hamabata H; Yuyang S; Jiaming L; Watanabe H
Antiviral Res; 2022 May; 201():105310. PubMed ID: 35358601
[TBL] [Abstract][Full Text] [Related]
40. A novel E198K substitution in the PA gene of influenza A virus with reduced susceptibility to baloxavir acid.
Takizawa N; Momose F
Arch Virol; 2022 Jul; 167(7):1565-1570. PubMed ID: 35511288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
